UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

The Genetic Basis for Cancer Treatment Decisions

Cell, 2012-02, Vol.148 (3), p.409-420

2012

Volltextzugriff (PDF)

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Cancer treatment reviews, 2013-12, Vol.39 (8), p.935-946

2013

Volltextzugriff (PDF)

Strategies for optimizing combinations of molecularly targeted anticancer agents

Nature reviews. Drug discovery, 2006-08, Vol.5 (8), p.649-659

2006

Volltextzugriff (PDF)

Therapeutic targets: MTOR and related pathways

Cancer biology & therapy, 2006-09, Vol.5 (9), p.1065-1073

Dancey, Janet E.

2006

Volltextzugriff (PDF)

Rare cancers: a sea of opportunity

The lancet oncology, 2016-02, Vol.17 (2), p.e52-e61

2016

Volltextzugriff (PDF)

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of clinical oncology, 2012-08, Vol.30 (23), p.2919-2928

2012

Volltextzugriff (PDF)

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3278-3285

2011

Volltextzugriff (PDF)

Cancer Genomics: Technology, Discovery, and Translation

Journal of clinical oncology, 2012-02, Vol.30 (6), p.647-660

2012

Volltextzugriff (PDF)

Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres

Frontiers in pharmacology, 2023, Vol.14, p.1294335-1294335

2023

Volltextzugriff (PDF)

Targeting epidermal growth factor receptor—are we missing the mark?

The Lancet (British edition), 2003-07, Vol.362 (9377), p.62-64

2003

Volltextzugriff (PDF)

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

The lancet oncology, 2009-03, Vol.10 (3), p.247-257

2009

Volltextzugriff (PDF)

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3978-3984

2007

Volltextzugriff (PDF)

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4921-4927

2008

Volltextzugriff (PDF)

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Supportive care in cancer, 2010-04, Vol.18 (4), p.509-522

2010

Volltextzugriff (PDF)

Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow

Cancer Cell, 2004-05, Vol.5 (5), p.411-415

Dancey, Janet E.

2004

Volltextzugriff (PDF)

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

American journal of clinical oncology, 2010-12, Vol.33 (6), p.609-613

2010

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6172-6180

2005

Volltextzugriff (PDF)

Clinical development of mammalian target of rapamycin inhibitors

Hematology/oncology clinics of North America, 2002-10, Vol.16 (5), p.1101-1114

Dancey, Janet E

2002

Volltextzugriff (PDF)

Clinical Development of Temsirolimus, a Novel mTOR Inhibitor, for Treatment of Advanced Malignancies

Seminars in oncology, 2009-12, Vol.36, p.S1-S2

2009

Volltextzugriff (PDF)

Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials

Seminars in oncology, 2009-12, Vol.36, p.S46-S58

2009

Volltextzugriff (PDF)

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome

European journal of cancer (1990), 2015-11, Vol.51 (17), p.2501-2507

2015

Volltextzugriff (PDF)

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

Leukemia research, 2009-11, Vol.33 (11), p.1475-1480

2009

Volltextzugriff (PDF)

Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: Factors Associated with Liver Toxicities

Journal of vascular and interventional radiology, 2005-02, Vol.16 (2), p.205-213

2005

Volltextzugriff (PDF)

The Globalization of Cooperative Groups

Seminars in oncology, 2015-10, Vol.42 (5), p.693-712

2015

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions

Current problems in cancer, 2009-07, Vol.33 (4), p.245-294

2009

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Humans
(49)
Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Oncology
(34)
Tumors
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Female
(19)
Male
(17)
Neoplasms - Drug Therapy
(17)
Hematology, Oncology And Palliative Medicine
(14)
Aged
(13)
Antineoplastic Agents - Therapeutic Use
(13)
Adult
(12)
Middle Aged
(12)
Clinical Trials
(10)
Treatment Outcome
(10)
Clinical Trials As Topic
(9)
Receptor, Epidermal Growth Factor - Antagonists & Inhibitors
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Genetic Basis for Cancer Treatment Decisions

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Strategies for optimizing combinations of molecularly targeted anticancer agents

Therapeutic targets: MTOR and related pathways

Rare cancers: a sea of opportunity

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Cancer Genomics: Technology, Discovery, and Translation

Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres

Targeting epidermal growth factor receptor—are we missing the mark?

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study

Clinical development of mammalian target of rapamycin inhibitors

Clinical Development of Temsirolimus, a Novel mTOR Inhibitor, for Treatment of Advanced Malignancies

Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: Factors Associated with Liver Toxicities

The Globalization of Cooperative Groups

Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions

Aktive Filter

Suchergebnisse filtern